Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.

OBJECTIVES: To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time. METHODS: We analysed 12-month outcomes in treatment-naïve eyes that started aflibercept or ranibizumab for nAMD (3802 eyes), DMO (975 eyes), Branch RVO (BRVO, 357 eyes), Central RVO (CRVO, 371 eyes) and Hemi-RVO (HRVO, 54 eyes) from 2015 and 2019 tracked in the prospectively designed observational Fight Retinal Blindness! Registry. RESULTS: The mean VA change at 12-month for each year between 2015 and 2019 remained stable or otherwise showed no discernible trends over time in eyes with nAMD (+3.3 to +6 letters), DMO (+3.6 to +6.7 letters) and RVO (+10.3 to +11.7 letters for BRVO, +5.9 to +17.7 letters for CRVO and 10.2 to 20.7 letters for HRVO). The median number of VEGF-inhibitor injections in eyes that completed 12-month follow-up also remained stable at 8-9 for nAMD, 6-7 for DMO, 7-9 for RVO. Fewer eyes (

Persistent anterior chamber silicone oil and myopia.

UNLABELLED: A 60-year-old man experienced a marked unilateral myopic shift of 20 diopters following attempted removal of intravitreal heavy silicone oil used in the treatment of inferior proliferative vitreoretinopathy following retinal detachment. Examination revealed heavy silicone oil adherent to the corneal endothelium and forming a convex interface with the aqueous, obscuring the entire pupil. Surgical intervention was required to restore visual acuity. The case highlights the potential ocular complications associated with silicone oil migration into the anterior chamber, including corneal endothelial decompensation and a significant increase in myopia. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.